SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support. ASAIO Journal 2020; 66:734-738.
Loforte A., Dal Checco E., Gliozzi G., Benedetto M., Cavalli G.G., Mariani C., et al. (2020). Veno-venous extracorporeal membrane oxygenation support in covid-19 respiratory distress syndrome: Initial experience. ASAIO JOURNAL, 66(7), 734-738 [10.1097/MAT.0000000000001198].
Veno-venous extracorporeal membrane oxygenation support in covid-19 respiratory distress syndrome: Initial experience
Loforte A.;Gliozzi G.;Cavalli G. G.;Mariani C.;Piccone G.;Agulli M.;Pacini D.;
2020
Abstract
SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support. ASAIO Journal 2020; 66:734-738.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
